ACIS · AI BIOTECH WEEKLY · ISSUE 001 · 2026.08.12
从平台故事，走向商业与临床验证
AI 生物科技研究周报｜第001期
Recursion、Schrödinger、Insilico 与大型药企合作持续推进。商业验证正在增强，但真正决定长期价值的仍是临床成功率。
01 · EXECUTIVE SUMMARY
执行摘要
AI 生物科技正在从“平台故事”走向合作验证、授权交易和临床验证。大型药企愿意支付前期款和里程碑，说明 AI 原生药物发现正在获得真实商业认可。
AI biotech is moving from platform narratives to partnership validation, licensing deals and clinical proof. Upfront and milestone payments from major pharma provide real commercial validation for AI-native drug discovery.
02 · PLATFORM WATCH
三家平台观察
Insilico 的授权与合作验证目前最强；Schrödinger 的软件、合作收入和自有管线更均衡；Recursion 的科学平台仍有吸引力，但需要更多收入与临床里程碑。
Insilico currently has the strongest licensing and partnership proof; Schrödinger offers a more balanced mix of software, collaboration revenue and pipeline value; Recursion remains scientifically compelling but needs more revenue and clinical milestones.
03 · BIG PHARMA SIGNAL
大型药企开始掏钱
近期多笔合作表明，大型药企愿意为 AI 药物发现能力支付真金白银。行业正从预测分子、生成候选药物，进入商业付款与临床验证阶段。
Recent deals show that major pharma is willing to pay for AI drug-discovery capability. The industry is moving from molecular prediction and candidate generation into commercial payments and clinical validation.
04 · INVESTMENT VIEW
机会与风险
板块配置第一优先级仍是 IBB 等分散工具；TechBio 个股更适合作为小比例卫星仓，并用里程碑而非故事决定加减仓。
Diversified exposure such as IBB remains the first priority. Individual TechBio names are better suited to small satellite positions, with sizing driven by milestones rather than narratives.
WEEKLY SCORECARD
本周评分
大型药企合作与授权付款带来更明确的商业验证。
平台价值开始接受商业付款与临床里程碑的双重检验。
分散配置优先，个股等待里程碑验证。